DRD2 and desmoplastic small round cell tumor: Recently, the promising results of a phase II trial (NCT03034200) evaluating an oral selective antagonist of the dopamine D2 receptor (ONC201) in neuroendocrine tumors and desmoplastic small round cell tumors (DSRCT) have been published, showing the greatest benefit especially in metastatic PPGLs.